We are live on
!
Find out more
WSL
Western Standard LLC Portfolio holdings
AUM
$190M
1-Year Est. Return
40.88%
This Fund
S&P 500
This Quarter
Est. Return
+9.18%
1 Year Est. Return
+40.88%
3 Year Est. Return
+68.87%
5 Year Est. Return
+221.93%
10 Year Est. Return
–
AUM
$217M
AUM Growth
-$120M
(-36%)
Cap. Flow
-$131M
Cap. Flow
% of AUM
-60.58%
Top 10 Holdings %
Top 10 Hldgs %
77.81%
Holding
37
New
13
Increased
5
Reduced
3
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Innospec
IOSP
|
+$18.2M |
| 2 |
Green Dot
GDOT
|
+$16.3M |
| 3 |
SEM
Select Medical
SEM
|
+$14.3M |
| 4 |
AIV
Aimco
AIV
|
+$10.1M |
| 5 |
Insperity
NSP
|
+$8.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keros Therapeutics
KROS
|
+$34.6M |
| 2 |
Consolidated Water Co
CWCO
|
+$7.47M |
| 3 |
National Presto Industries
NPK
|
+$6.81M |
| 4 |
Bath & Body Works
BBWI
|
+$6.78M |
| 5 |
Abeona Therapeutics
ABEO
|
+$6.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.36% |
| 2 | Financials | 25.12% |
| 3 | Materials | 9.48% |
| 4 | Consumer Discretionary | 9.46% |
| 5 | Industrials | 8.38% |
Similar funds
RCAP
HCM
CFA
CCA
G
BC
SCM
BCPWM
Western Standard LLC's Q4 2025 Portfolio in Review
As of Q4 2025, Western Standard LLC held 37 positions worth $217M, down 36% from $337M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Western Standard LLC withdrew a net $131M in Q4 2025, closing 12 positions and reducing 3 holdings. Its most notable exit was Keros Therapeutics, an estimated $34.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 22% a quarter earlier, followed by Financials and Materials.
Against the trend, Western Standard LLC opened a new position in Aimco worth $9.98M.
- Western Standard LLC's largest Q4 2025 buy was Aimco: 1,679,924 shares worth $9.98M.
- Western Standard LLC added most to Innospec in Q4 2025, an estimated $18.2M increase.
- Western Standard LLC's biggest Q4 2025 reduction was Driven Brands, cutting an estimated $5.8M.
- Western Standard LLC fully exited Keros Therapeutics in Q4 2025, selling an estimated $34.6M.
- Western Standard LLC's ten largest holdings make up 78% of its $217M portfolio in Q4 2025.
- Western Standard LLC opened 13 new positions and closed 12 in Q4 2025.
- Western Standard LLC's portfolio value fell 36% quarter-over-quarter to $217M.
Based on Western Standard LLC's 13F filing for Q4 2025, filed 3 Feb 2026.